Market Overview on Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 - Pipeline Review, H1 2016

Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H1 2016 ​is a new market research publication announced by Reportstack. This report provides in depth analysis on Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted pipeline therapeutics.

The report provides comprehensive information on the Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics development and features dormant and discontinued projects.

To access full report with TOC, please visit Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 - Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report reviews key players involved in Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report reviews latest news and deals related to Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Devise corrective measures for pipeline projects by understanding Corticosteroid 11-Beta-Dehydrogenase Isozyme 1 (11-Beta-Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or 11-DH or 11-beta-HSD1 or HSD11B1 or EC 1.1.1.146) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Actinogen Limited Astellas Pharma Inc. AstraZeneca Plc Connexios Life Sciences Pvt. Ltd. F. Hoffmann-La Roche Ltd. Hyundai Pharmaceutical Co., Ltd. Merck & Co., Inc. Pfizer Inc. Poxel SA Sanofi Shanghai Pharmaceutical Co., Ltd. SK Chemicals Co., Ltd. Sumitomo Dainippon Pharma Co., Ltd. Toray Industries, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###